Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer

By LabMedica International staff writers
Posted on 23 Oct 2026

High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. More...

Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair. Identifying HRD currently requires sophisticated genetic analysis that can be costly, time-consuming, and difficult to access in lower-resource settings. A new study points to a potentially more accessible approach, showing that artificial intelligence can identify signs of HRD from routine tissue images.

King’s College London researchers developed HRDPath, an explainable multi-model deep learning architecture that predicts HRD from histopathology images. The system evaluates high-resolution digital microscopy images of tumor tissue rather than analyzing DNA directly. To train it, the team used tissue images from patients whose HRD status had already been established through genomic analysis. This allowed HRDPath to learn visual features that distinguish HRD-positive from HRD-negative cancers.

The study focused on high-grade serous tubo-ovarian carcinoma, assessing whether image-based analysis could identify tumors with defective DNA repair mechanisms. HRD can result from mutations in genes such as BRCA1 and BRCA2, which leave cancer cells less able to repair DNA damage. This weakness can make the cells more vulnerable to platinum-based chemotherapy and poly(ADP-ribose) polymerase inhibitors, making HRD a valuable biomarker for treatment selection.

HRDPath showed promising accuracy, particularly when several images from the same patient were considered. Under those conditions, it correctly identified approximately 91% of HRD-positive cases. The researchers also found that HRD-positive tumors showed subtle differences in cancer cell appearance and organization, including rounder cell nuclei and more densely packed cancer cells in some tumor regions. The findings were published in Nature Communications on October 21, 2026.

The researchers stated that further validation in larger patient populations is needed. They also said HRDPath could help reduce reliance on expensive genetic testing if HRD status can be reliably determined from tissue images already acquired for diagnosis. The work suggests that AI analysis may identify tissue-level changes linked to DNA repair defects that may be difficult to recognize by conventional examination.

“We are unlocking information hidden in microscopic images of cancer tissue that could transform how we match patients to treatments. By using AI to reveal defects in DNA repair, we could make precision cancer medicine faster, more affordable and accessible to more women with ovarian cancer, not just in the U.K. but around the world,” said Dr. Heba Sailem, reader in computational pathology at King’s College London.

Related Links
King’s College London 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.